Press release

Valbiotis strengthens its financial resources to support the ramp-up of its commercial activity

New non-dilutive bank financing from Société Générale, BNP Paribas and Bpifrance, and implementation of a factoring agreement

La Rochelle, November 16, 2026 (5:40 PM CET) **– Valbiotis** (FR0013254851 – ALVAL, PEA/PME eligible), a French laboratory specializing in cardiometabolic health, announces new bank financing totaling €1.65M, as well as the signing of a factoring agreement with BNP Paribas Factor. These resources supplement the Company's existing cash position and provide additional flexibility to support the ramp-up of its commercial activity, without dilution for its shareholders. Granted by its two long-standing banks and by Bpifrance, this financing demonstrates Valbiotis' ability to mobilize leading financial partners in support of its development.

Sébastien Peltier, Chairman of the Management Board of Valbiotis, states*: "The renewed confidence of our long-standing banking partners and Bpifrance is a strong signal. It illustrates our ability to secure financing tailored to each stage of our development. These resources supplement our cash position and give us the means to support, under the best possible conditions, the ramp-up of our sales, particularly in pharmacies."*

Three loans totaling €1.65M

Valbiotis has obtained three non-dilutive loans, all at fixed rates:

- two loans of €600K each, with a 4-year term, granted by its two long-standing banking partners, Société Générale and BNP Paribas;
- one loan of €450K granted by Bpifrance, with a total term of 8 years, including a 3-year repayment deferral followed by a 5-year amortization period.

A factoring agreement to support commercial growth in pharmacies

In parallel, Valbiotis has signed a factoring agreement (trade receivables financing) with BNP Paribas Factor, with a total authorized funding limit of €500K, which may be increased at any time during the

term of the agreement in line with business growth. This facility is intended to finance the working capital requirement related to trade receivables, which is expected to grow with the anticipated ramp-up of revenue in the pharmacy channel, where payment terms are 45 days end of month.

Resources that supplement the Company's cash position and strengthen Valbiotis' financing capacity

This financing comes in addition to the €11.7M in cash held by Valbiotis as of June 30, 2026, which provides the Company with a cash runway through the end of 2027, excluding any additional sources of financing. By dedicating specific instruments to financing its growth – amortizing loans and trade receivables factoring – Valbiotis strengthens its financial flexibility and can allocate its resources as a priority to the commercial rollout of its products, without dilution for its shareholders.

Beyond the amounts involved, this financing is a sign of confidence: the renewed support of its two long-standing banks, alongside Bpifrance, illustrates the lasting relationship Valbiotis has built with its financial partners and its ability to mobilize diversified resources tailored to each stage of its development.

Shareholder benefit

20% discount on all products from Valbiotis$^{PRO®}$ and Valbiotis$^{PLUS®}$ granted by customer service (service-client@valbiotis.com) upon proof of ownership of at least 85 shares.

Details of the terms: click here

About Valbiotis

Valbiotis is a French laboratory, founded in 2014 in La Rochelle, that designs and markets clinically tested natural health products dedicated to cardiometabolic health. Its ValbiotisPRO® range is based on patented active substances evaluated in randomized, placebo-controlled clinical studies; its ValbiotisPLUS® range supports everyday health. Its products are distributed in pharmacies and online in France, and internationally through partners, including a joint venture in China, Hangzhou Valbiotis Life Health Technology Co. Ltd. Valbiotis aims to become an international leader in natural health products dedicated to cardiometabolic health. Valbiotis is a PEA-PME eligible company.

For more information on Valbiotis®, please visit: www.valbiotis.com and the investor section: https://investisseurs.valbiotis.com/investisseurs/

Contacts

Corporate Communications / **Valbiotis**
Caroline LAMBERTI
+33 6 77 82 56 88
caroline.lamberti@valbiotis.com

Financial Communications / **Seitosei.Actifin**
Marianne PY
+33 6 85 52 76 93
marianne.py@seitosei-actifin.com

Press Relations / **LJ Com by JIN**

Valentine MARTIN
+33 6 32 29 43 82
v.martin@ljcom.net

Name: Valbiotis
ISIN code: FR0013254851
Ticker symbol: ALVAL
EnterNext© PEA-PME 150

This press release contains forward-looking statements concerning Valbiotis' objectives. Valbiotis considers that these projections are based on information currently available to Valbiotis and on reasonable assumptions. However, they in no way constitute guarantees of future performance and may be called into question by changes in economic conditions and financial markets, and by a number of risks and uncertainties, including those described in section 3 "Risk Factors" of Valbiotis' Universal Registration Document filed with the French Financial Markets Authority (Autorité des marchés financiers – AMF) on April 20, 2026, available on the Company's website (www.valbiotis.com).

This press release and the information it contains do not constitute an offer to sell or subscribe for, or a solicitation of an order to purchase or subscribe for, Valbiotis shares or financial securities in any country.